Last reviewed · How we verify

Poractant alfa instillation

Poznan University of Medical Sciences · FDA-approved active Small molecule

Poractant alfa instillation is a Pulmonary surfactant replacement Small molecule drug developed by Poznan University of Medical Sciences. It is currently FDA-approved for Respiratory distress syndrome in premature infants, Acute respiratory distress syndrome (ARDS).

Poractant alfa is a natural pulmonary surfactant that replaces deficient or dysfunctional surfactant in the lungs to restore normal respiratory function.

Poractant alfa is a natural pulmonary surfactant that replaces deficient or dysfunctional surfactant in the lungs to restore normal respiratory function. Used for Respiratory distress syndrome in premature infants, Acute respiratory distress syndrome (ARDS).

At a glance

Generic namePoractant alfa instillation
SponsorPoznan University of Medical Sciences
Drug classPulmonary surfactant replacement
TargetPulmonary surfactant (lipid and protein complex)
ModalitySmall molecule
Therapeutic areaRespiratory/Pulmonology
PhaseFDA-approved

Mechanism of action

Poractant alfa is derived from porcine lung tissue and contains the key surfactant proteins and lipids necessary for reducing surface tension in the alveoli. By restoring surfactant function, it improves lung compliance, reduces work of breathing, and prevents alveolar collapse, particularly in conditions characterized by surfactant deficiency or dysfunction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Poractant alfa instillation

What is Poractant alfa instillation?

Poractant alfa instillation is a Pulmonary surfactant replacement drug developed by Poznan University of Medical Sciences, indicated for Respiratory distress syndrome in premature infants, Acute respiratory distress syndrome (ARDS).

How does Poractant alfa instillation work?

Poractant alfa is a natural pulmonary surfactant that replaces deficient or dysfunctional surfactant in the lungs to restore normal respiratory function.

What is Poractant alfa instillation used for?

Poractant alfa instillation is indicated for Respiratory distress syndrome in premature infants, Acute respiratory distress syndrome (ARDS).

Who makes Poractant alfa instillation?

Poractant alfa instillation is developed and marketed by Poznan University of Medical Sciences (see full Poznan University of Medical Sciences pipeline at /company/poznan-university-of-medical-sciences).

What drug class is Poractant alfa instillation in?

Poractant alfa instillation belongs to the Pulmonary surfactant replacement class. See all Pulmonary surfactant replacement drugs at /class/pulmonary-surfactant-replacement.

What development phase is Poractant alfa instillation in?

Poractant alfa instillation is FDA-approved (marketed).

What are the side effects of Poractant alfa instillation?

Common side effects of Poractant alfa instillation include Transient oxygen desaturation, Bradycardia, Reflux of instillate into endotracheal tube, Pulmonary hemorrhage.

What does Poractant alfa instillation target?

Poractant alfa instillation targets Pulmonary surfactant (lipid and protein complex) and is a Pulmonary surfactant replacement.

Related